270 related articles for article (PubMed ID: 30674687)
1. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M
Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review.
Préaud E; Largeron N
J Med Econ; 2013; 16(6):763-76. PubMed ID: 23565814
[TBL] [Abstract][Full Text] [Related]
3. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
Medeiros R; Vaz S; Rebelo T; Figueiredo-Dias M
Acta Med Port; 2020 Mar; 33(3):198-201. PubMed ID: 32130098
[TBL] [Abstract][Full Text] [Related]
4. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Watson M; Lowy DR; Markowitz LE
Vaccine; 2012 Sep; 30(42):6016-9. PubMed ID: 22867718
[TBL] [Abstract][Full Text] [Related]
5. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
Luttjeboer J; Westra TA; Wilschut JC; Nijman HW; Daemen T; Postma MJ
Vaccine; 2013 Aug; 31(37):3922-7. PubMed ID: 23806241
[TBL] [Abstract][Full Text] [Related]
7. Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group.
Marcellusi A; Capone A; Favato G; Mennini FS; Baio G; Haeussler K; Bononi M;
Clin Ther; 2015 Jan; 37(1):156-167.e4. PubMed ID: 25487083
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
10. The economic burden of noncervical human papillomavirus disease in the United States.
Hu D; Goldie S
Am J Obstet Gynecol; 2008 May; 198(5):500.e1-7. PubMed ID: 18455524
[TBL] [Abstract][Full Text] [Related]
11. Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark.
Olsen J; Jørgensen TR; Kofoed K; Larsen HK
BMC Public Health; 2012 Dec; 12():1082. PubMed ID: 23244352
[TBL] [Abstract][Full Text] [Related]
12. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom.
Woodhall SC; Jit M; Cai C; Ramsey T; Zia S; Crouch S; Birks Y; Newton R; Edmunds WJ; Lacey CJ
Sex Transm Dis; 2009 Aug; 36(8):515-21. PubMed ID: 19543143
[TBL] [Abstract][Full Text] [Related]
13. Health and economic implications of HPV vaccination in the United States.
Kim JJ; Goldie SJ
N Engl J Med; 2008 Aug; 359(8):821-32. PubMed ID: 18716299
[TBL] [Abstract][Full Text] [Related]
14. [AN HPV-ASSOCIATED DISEASES AND CERVICAL CANCER AND PROPHYLACTIC HUMAN PAPILLOMAVIRUS (HPV) VACCINES].
Malinova M
Akush Ginekol (Sofiia); 2015; 54 Suppl 1():25-31. PubMed ID: 26137767
[TBL] [Abstract][Full Text] [Related]
15. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art.
Toh ZQ; Licciardi PV; Fong J; Garland SM; Tabrizi SN; Russell FM; Mulholland EK
Vaccine; 2015 Sep; 33(39):5042-50. PubMed ID: 26271829
[TBL] [Abstract][Full Text] [Related]
16. Quality of life valuations of HPV-associated cancer health states by the general population.
Conway EL; Farmer KC; Lynch WJ; Rees GL; Wain G; Adams J
Sex Transm Infect; 2012 Nov; 88(7):517-21. PubMed ID: 22645393
[TBL] [Abstract][Full Text] [Related]
17. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
[TBL] [Abstract][Full Text] [Related]
18. Incidence, cost and gender differences of oropharyngeal and noncervical anogenital cancers in South Korea.
Choi I; Lee D; Son KB; Bae S
BMC Public Health; 2020 Jun; 20(1):1035. PubMed ID: 32600300
[TBL] [Abstract][Full Text] [Related]
19. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
20. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.
Arbyn M; de Sanjosé S; Saraiya M; Sideri M; Palefsky J; Lacey C; Gillison M; Bruni L; Ronco G; Wentzensen N; Brotherton J; Qiao YL; Denny L; Bornstein J; Abramowitz L; Giuliano A; Tommasino M; Monsonego J
Int J Cancer; 2012 Nov; 131(9):1969-82. PubMed ID: 22623137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
